BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 29, 2019
View Archived Issues
"Membrane-anchored molecular adjuvant" improves rabies vaccine
Read More
Sorting chimeras from fata morganas
Read More
'Deep cultivation' used to describe 79 previously uncharacterized planctomycetal strains
Read More
Roche initiates first-in-human study of RO-7247669
Read More
KM Biologics presents dengue vaccine tested in monkeys
Read More
OBI Pharma opens enrollment in phase I/II study of OBI-999 in advanced solid tumors
Read More
DP-13 begins phase II trial in primary aldosteronism
Read More
New analgesic target and lead compound identified in rodents
Read More
TIFA as a new predictive biomarker of PAH
Read More
G. mellonella as a promising in vivo model for assessing the pathogenesis of GBS
Read More
Roche presents phase III data for atezolizumab plus bevacizumab in HCC
Read More
KY-1043 demonstrates potent antitumor activity in vitro and in vivo
Read More
Enrollment ongoing in phase II study of ciprofloxacin/celecoxib fixed-dose combination
Read More
First-in-human study of 89Zr-DFO-REGN-3504 for imaging PD-L1 tumors
Read More
Prestige Biopharma initiates phase III study of proposed biosimilar HD-204
Read More
Array BioPharma, Mirati Therapeutics describe new G12C-mutant GTPase KRAS inhibitors
Read More
Incyte patents PD-1/PD-L1 interaction inhibitors
Read More
New anticancer compounds discovered at Zymeworks
Read More
Bionomics presents Nav1.7 channel blockers
Read More
Gilead Sciences is enrolling participants in phase II study of GS-4875
Read More
NMPA approves flumatinib mesylate for the treatment of Ph+ chronic myeloid leukemia
Read More
GSK-3527497, a new preclinical candidate for effective inhibition of TRPV4
Read More
The enteropeptidase inhibitor SCO-792 enters phase II development
Read More
PEG12KL4: a new RNA pulmonary delivery vector with confirmed in vivo transfection efficiency
Read More
FUEL trial shows effects of udenafil on exercise in single ventricle heart disease
Read More